Alzamend Neuro (ALZN) Competitors $1.27 +0.01 (+0.79%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALZN vs. CVM, ATHE, CVKD, LVTX, PULM, INKT, LSTA, NKGN, ENLV, and LPCNShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include CEL-SCI (CVM), Alterity Therapeutics (ATHE), Cadrenal Therapeutics (CVKD), LAVA Therapeutics (LVTX), Pulmatrix (PULM), MiNK Therapeutics (INKT), Lisata Therapeutics (LSTA), NKGen Biotech (NKGN), Enlivex Therapeutics (ENLV), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. CEL-SCI Alterity Therapeutics Cadrenal Therapeutics LAVA Therapeutics Pulmatrix MiNK Therapeutics Lisata Therapeutics NKGen Biotech Enlivex Therapeutics Lipocine CEL-SCI (NYSE:CVM) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking. Which has more risk and volatility, CVM or ALZN? CEL-SCI has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Is CVM or ALZN more profitable? Alzamend Neuro's return on equity of 0.00% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -239.31% -102.69% Alzamend Neuro N/A N/A -568.88% Does the MarketBeat Community favor CVM or ALZN? Alzamend Neuro received 6 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 100.00% of users gave Alzamend Neuro an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes10100.00% Alzamend NeuroOutperform Votes6100.00% Underperform VotesNo Votes Do insiders and institutionals hold more shares of CVM or ALZN? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 16.2% of CEL-SCI shares are owned by company insiders. Comparatively, 10.6% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate CVM or ALZN? Alzamend Neuro has a consensus target price of $32.00, indicating a potential upside of 2,439.68%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, CVM or ALZN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$32.19M-$0.58-0.74Alzamend NeuroN/AN/A-$9.95MN/AN/A Does the media favor CVM or ALZN? In the previous week, Alzamend Neuro had 1 more articles in the media than CEL-SCI. MarketBeat recorded 5 mentions for Alzamend Neuro and 4 mentions for CEL-SCI. Alzamend Neuro's average media sentiment score of 1.88 beat CEL-SCI's score of 0.17 indicating that Alzamend Neuro is being referred to more favorably in the news media. Company Overall Sentiment CEL-SCI Neutral Alzamend Neuro Very Positive SummaryAlzamend Neuro beats CEL-SCI on 10 of the 13 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.85M$6.64B$5.22B$9.05BDividend YieldN/A2.92%4.99%4.19%P/E RatioN/A10.7888.0517.31Price / SalesN/A201.161,103.55127.59Price / CashN/A57.1143.2637.86Price / Book-0.365.265.185.19Net Income-$9.95M$153.48M$121.70M$226.98M7 Day Performance5.00%5.66%4.64%3.22%1 Month Performance10.53%0.22%21.59%4.45%1 Year Performance-86.74%7.04%32.00%21.75% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro3.2084 of 5 stars$1.27+0.8%$32.00+2,419.7%-86.7%$6.90MN/A0.004Positive NewsGap UpCVMCEL-SCIN/A$0.41-32.3%N/A-81.7%$25.94MN/A-0.7043High Trading VolumeATHEAlterity Therapeutics2.8153 of 5 stars$3.50+11.5%$6.00+71.4%+99.1%$25.57MN/A0.0010Positive NewsGap UpHigh Trading VolumeCVKDCadrenal Therapeutics2.5869 of 5 stars$14.23-11.9%$32.00+124.9%N/A$25.37MN/A-2.134Gap DownLVTXLAVA Therapeutics2.8456 of 5 stars$0.99-0.3%$3.33+236.7%-41.1%$25.10M$7.35M-0.9660PULMPulmatrix0.0495 of 5 stars$6.86+7.2%N/A+246.2%$25.05M$10.01M-2.6020Analyst ForecastNews CoverageINKTMiNK Therapeutics2.4428 of 5 stars$0.63+9.6%$6.50+931.7%-14.7%$24.97MN/A-1.6230LSTALisata Therapeutics2.4201 of 5 stars$2.94-2.6%$15.00+410.2%+30.5%$24.68MN/A-1.1730Gap UpNKGNNKGen BiotechN/A$0.70-2.3%N/A-75.0%$24.65M$80,000.00-0.14N/AENLVEnlivex Therapeutics2.619 of 5 stars$1.15-3.4%$9.50+726.1%-65.5%$24.62MN/A-1.1770Gap DownLPCNLipocine1.4551 of 5 stars$4.58-3.8%$10.00+118.3%+75.1%$24.49M$7.92M-6.0310Gap Up Related Companies and Tools Related Companies CEL-SCI Competitors Alterity Therapeutics Competitors Cadrenal Therapeutics Competitors LAVA Therapeutics Competitors Pulmatrix Competitors MiNK Therapeutics Competitors Lisata Therapeutics Competitors NKGen Biotech Competitors Enlivex Therapeutics Competitors Lipocine Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALZN) was last updated on 1/6/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored$24 trillion tech spotted at Mar-a-Lago?President Trump’s Secret Service was recently spotted using an odd new technology at his home in Mar-a-Lago…Centurion Publishing | SponsoredFrom bankrupt to delivering 610,000% returnsWalk the empty streets of this barren town and you would have no idea that behind the sand-scarred blight is o...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredBank of America just did this with NvidiaThanks to Nvidia’s continued AI dominance and reflecting its growth potential … Bank of America recently ma...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.